fdfd12 wrote: I use technical analysis.
When the stock price going below $25.04 and staying there or lower for a few days, CXR is doomed. It is all technical analysis predictions. When the stock was $40, I said, if the stock goes to $30, sell half and below $25, sell other half.
BUT, if it goes belwo 30 as it is now, and then goes above 30 next week, you buy the half that yousold.
Similarly to 25. Sell all but once it goes back above 25, buy the half back.
The Europe price control may come in 2 years from now. If it comes in 2 years, CXR's price will still be below $35 since the market looks ahead.
They may do $6.50US this year and next also, but in 2018 if they toughen up the laws, then
reductions will come to guidance.
If CXR is truely a great stock, the price should not be acting like this.
POINT FINALE!!!!!!
Remember, a stock to get to 0, it has to pass by 30 then 25 then 20 etc...
This is the reasoning I am using.
Why are they shorting this more than VRX?
That is what has me baffled.
Longboarder wrote: fdfd12,
I've been watching this board for quite some time and generally I try to keep quiet and avoid calling out other posters. However, two things you have said over and over again are starting to get to me and I would like you to provide further rationale:
1) How will CXR go bankrupt if sp hits $25. You have said this is as it is a fact. So what about the $25 target is so absolutley devastating that it will bankrupt the company? Will CXR's drug portfiolio magicaly disapear and their cash flow will cease to exist? Or will Cohodes attack the CXR headquarters with his hoard of chickens? Please explain
2) Do you actually beleive that the political nonsense regarding pricing will cut CXR's earnings from $6.50 to $3.00, a more than 50% drop? I have personally never heard of drug pricing legislation that can be that devastating, so please provide some intelligent rationale for this claim. And for everyone's sake don't use the Big Mac example, comparing burgers and drugs is quite possible the worst analogy you can make.